MicroRNA-143/-145 in cardiovascular diseases

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Zhao, Wang ^a   Zhao, Shui Ping ^a   Zhao, Yu Hong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 143; MICRORNA 145; BIOLOGICAL MARKER; MICRORNA;

ACTIN FILAMENT; ACUTE HEART INFARCTION; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CORONARY ARTERY DISEASE; ESSENTIAL HYPERTENSION; HUMAN; INFLAMMATORY CELL; PULMONARY HYPERTENSION; REVIEW; SHEAR STRESS; UNSTABLE ANGINA PECTORIS; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY;

EID: 84937057122     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/531740     Document Type: Review

References (82)

1. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function," Cell, vol. 116, no. 2, pp. 281-297, 2004.
2. I. Bentwich, A. Avniel, Y. Karov et al., "Identification of hundreds of conserved and nonconserved human microRNAs," Nature Genetics, vol. 37, no. 7, pp. 766-770, 2005.
3. R. C. Friedman, K. K.-H. Farh, C. B. Burge, and D. P. Bartel, "Most mammalian mRNAs are conserved targets of microRNAs," Genome Research, vol. 19, no. 1, pp. 92-105, 2009.
4. E. M. Small and E. N. Olson, "Pervasive roles ofmicroRNAs in cardiovascular biology," Nature, vol. 469, no. 7330, pp. 336-342, 2011.
5. L. He and G. J. Hannon, "MicroRNAs: small RNAs with a big role in gene regulation," Nature Reviews Genetics, vol. 5, no. 7, pp. 522-531, 2004.
6. A. Y. Rangrez, Z. A. Massy, V. M.-L. Meuth, and L. Metzinger, "MiR-143 and miR-145 molecular keys to switch the phenotype of vascular smooth muscle cells," Circulation: Cardiovascular Genetics, vol. 4, no. 2, pp. 197-205, 2011.
7. F. de Santa, I. Iosue, A. Del Rio, and F. Fazi, "MicroRNA biogenesis pathway as a therapeutic target for human disease and cancer," Current Pharmaceutical Design, vol. 19, no. 4, pp. 745-764, 2013.
8. S. Hagiwara, P. Kantharidis, and M. Cooper, "MicroRNA as biomarkers and regulator of cardiovascular development and disease," Current Pharmaceutical Design, vol. 20, no. 14, pp. 2347-2370, 2014.
9. L. A. MacFarlane and P. R. Murphy, "MicroRNA: biogenesis, function and role in cancer," Current Genomics, vol. 11, no. 7, pp. 537-561, 2010.
10. C.Wang, B. Ji, B. Cheng, J. Chen, and B. Bai, "Neuroprotection of microRNA in neurological disorders (Review)," Biomedical Reports, vol. 2, no. 5, pp. 611-619, 2014.
11. D. S. Greenberg and H. Soreq, "MicroRNA therapeutics in neurological disease," Current Pharmaceutical Design, vol. 20, no. 38, pp. 6022-6027, 2014.
12. M. V. Iorio and C. M. Croce, "MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review," EMBO Molecular Medicine, vol. 4, no. 3, pp. 143-159, 2012.
13. E. van Rooij and E. N. Olson, "MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles," Nature Reviews Drug Discovery, vol. 11, no. 11, pp. 860-872, 2012.
14. K. R. Cordes and D. Srivastava, "MicroRNA regulation of cardiovascular development," Circulation Research, vol. 104, no. 6, pp. 724-732, 2009.
15. M. V. G. Latronico and G. Condorelli, "MicroRNAs and cardiac pathology," Nature Reviews. Cardiology, vol. 6, no. 6, pp. 419-429, 2009.
16. K. C. Vickers, K.-A. Rye, and F. Tabet, "MicroRNAs in the onset and development of cardiovascular disease," Clinical Science, vol. 126, no. 3, pp. 183-194, 2014.
17. P. Jakob and U. Landmesser, "Role of microRNAs in stem/progenitor cells and cardiovascular repair," Cardiovascular Research, vol. 93, no. 4, pp. 614-622, 2012.
18. S. Kumar, C. W. Kim, R. D. Simmons, and H. Jo, "Role of flow-sensitive micrornas in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 10, pp. 2206-2216, 2014.
19. M. A. Listowski, E. Heger, D. M. Bogusławska et al., "MicroRNAs: fine tuning of erythropoiesis," Cellular and Molecular Biology Letters, vol. 18, no. 1, pp. 34-46, 2013.
20. T. Marin, B. Gongol, Z. Chen et al., "Mechanosensitive microRNAs-role in endothelial responses to shear stress and redox state,"Free Radical Biology and Medicine, vol. 64, pp. 61-68, 2013.
21. M. S. Parmacek, "MicroRNA-modulated targeting of vascular smooth muscle cells," Journal of Clinical Investigation, vol. 119, no. 9, pp. 2526-2528, 2009.
22. T. Alexy, A. M. James, and C. D. Searles, "Shear sensitive microRNAs and atherosclerosis," Biorheology, vol. 51, no. 2-3, pp. 147-158, 2014.
23. I. Elzenaar, Y. M. Pinto, and R. J. Van Oort, "MicroRNAs in heart failure: new targets in disease management," Clinical Pharmacology and Therapeutics, vol. 94, no. 4, pp. 480-489, 2013.
24. V. Sala, S. Bergerone, S. Gatti et al., "MicroRNAs in myocardial ischemia: Identifying new targets and tools for treating heart disease. New frontiers for miR-medicine," Cellular and Molecular Life Sciences, vol. 71, no. 8, pp. 1439-1452, 2014.
25. A. Synetos, K. Toutouzas, K. Stathogiannis et al., "MicroRNAs in arterial hypertension,"Current Topics inMedicinal Chemistry, vol. 13, no. 13, pp. 1527-1532, 2013.
26. L. N. L. van Aelst and S. Heymans, "MicroRNAs as biomarkers for ischemic heart disease," Journal of Cardiovascular Translational Research, vol. 6, no. 4, pp. 458-470, 2013.
27. H.-J. Xing, Y.-J. Li, Q.-M. Ma et al., "Identification of microRNAs present in congenital heart disease associated copy number variants," European Review for Medical and Pharmacological Sciences, vol. 17, no. 15, pp. 2114-2120, 2013.
28. C.Weber, A. Schober, and A. Zernecke, "MicroRNAs in arterial remodelling, inflammation and atherosclerosis," Current Drug Targets, vol. 11, no. 8, pp. 950-956, 2010.
29. T. Boettger, N. Beetz, S. Kostin et al., "Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster," Journal of Clinical Investigation, vol. 119, no. 9, pp. 2634-2647, 2009.
30. Y. Cheng, X. Liu, J. Yang et al., "MicroRNA-145, a novel smoothmuscle cell phenotypic marker andmodulator, controls vascular neointimal lesion formation," Circulation Research, vol. 105, no. 2, pp. 158-166, 2009.
31. K. R. Cordes, N. T. Sheehy, M. P. White et al., "miR-145 and miR-143 regulate smooth muscle cell fate and plasticity," Nature, vol. 460, no. 7256, pp. 705-710, 2009.
32. D. C. Deacon, K. R. Nevis, T. J. Cashman et al., "The miR-143-adducin3 pathway is essential for cardiac chambermorphogenesis," Development, vol. 137, no. 11, pp. 1887-1896, 2010.
33. E. Hergenreider, S. Heydt, K. Tréguer et al., "Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs," Nature Cell Biology, vol. 14, no. 3, pp. 249-256, 2012.
34. Y. D'Alessandra, M. C. Carena, L. Spazzafumo et al., "Diagnostic potential of plasmatic microRNA signatures in stable and unstable angina," PLoS ONE, vol. 8, no. 11, Article ID e80345, 2013.
35. S. Fichtlscherer, S. De Rosa, H. Fox et al., "Circulating microRNAs in patients with coronary artery disease," Circulation Research, vol. 107, no. 5, pp. 677-684, 2010.
36. B. Meder, A. Keller, B. Vogel et al., "MicroRNA signatures in total peripheral blood as novel biomarkers for acutemyocardial infarction," Basic Research in Cardiology, vol. 106, no. 1, pp. 13-23, 2011.
37. P. Caruso, Y. Dempsie, H. C. Stevens et al., "Arole for miR-145 in pulmonary arterial hypertension: evidence frommouse models and patient samples," Circulation Research, vol. 111, no. 3, pp. 290-300, 2012.
38. J. E.Kontaraki, M. E.Marketou, E.A. Zacharis, F. I. Parthenakis, and P. E. Vardas, "Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension," Journal ofHumanHypertension, vol. 28,no. 8, pp. 510-516, 2014.
39. D. Santovito, C. Mandolini, P. Marcantonio et al., "Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients," Expert Opinion on Therapeutic Targets, vol. 17, no. 3, pp. 217-223, 2013.
40. Y. Wei, M. Nazari-Jahantigh, P. Neth, C. Weber, and A. Schober, "MicroRNA-126,-145, and-155: a therapeutic triad in atherosclerosis?" Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 3, pp. 449-454, 2013.
41. S. Albinsson and K. Swärd, "Targeting smooth muscle microRNAs for therapeutic benefit in vascular disease," Pharmacological Research, vol. 75, pp. 28-36, 2013.
42. M. Xin, E. M. Small, L. B. Sutherland et al., "MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury," Genes and Development, vol. 23, no. 18, pp. 2166-2178, 2009.
43. L. Elia, M. Quintavalle, J. Zhang et al., "Theknockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease," Cell Death & Differentiation, vol. 16, no. 12, pp. 1590-1598, 2009.
44. K. Endo, H. Weng, Y. Naito et al., "Classification of various muscular tissues using miRNA profiling," Biomedical Research, vol. 34, no. 6, pp. 289-299, 2013.
45. S. Yamaguchi, K. Yamahara, K. Homma et al., "The role of microRNA-145 in human embryonic stem cell differentiation into vascular cells," Atherosclerosis, vol. 219, no. 2, pp. 468-474, 2011.
46. M. Quintavalle, L. Elia, G. Condorelli, and S. A. Courtneidge, "MicroRNAcontrol of podosome formation in vascular smooth muscle cells in vivo and in vitro," Journal of Cell Biology, vol. 189, no. 1, pp. 13-22, 2010.
47. S. Albinsson, Y. Suarez, A. Skoura, S. Offermanns, J. M. Miano, and W. C. Sessa, "MicroRNAs are necessary for vascular smooth muscle growth, differentiation, and function," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 6, pp. 1118-1126, 2010.
48. M. M. N. Schmitt, R. T. A. Megens, A. Zernecke et al., "Endothelial junctional adhesion molecule-a guides monocytes into flow-dependent predilection sites of atherosclerosis," Circulation, vol. 129, no. 1, pp. 66-76, 2014.
49. N. Ma and X. Gao, "β-actin is predicted as one of the potential targets of miR-145: choose internal control gene in verification of microRNA target," Carcinogenesis, vol. 34, no. 1, article 236, 2013.
50. R. A. Boon, T. A. Leyen, R. D. Fontijn et al., "KLF2-induced actin shear fibers control both alignment to flow and JNK signaling in vascular endothelium," Blood, vol. 115, no. 12, pp. 2533-2542, 2010.
51. R. Li, G. Yan, Q. Zhang et al., "miR-145 inhibits isoproterenolinduced cardiomyocyte hypertrophy by targeting the expression and localization of GATA6," FEBS Letters, vol. 587, no. 12, pp. 1754-1761, 2013.
52. K. Y. Miyasaka, Y. S. Kida, T. Banjo et al., "Heartbeat regulates cardiogenesis by suppressing retinoic acid signaling via expression of miR-143," Mechanisms of Development, vol. 128, no. 1-2, pp. 18-28, 2011.
53. M. Blumensatt, S. Greulich, D. Herzfeld DeWiza et al., "Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143," Cardiovascular Research, vol. 100, no. 2, pp. 201-210, 2013.
54. S. V. Naga Prasad, Z.-H. Duan, M. K. Gupta et al., "Unique MicroRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks," The Journal of Biological Chemistry, vol. 284, no. 40, pp. 27487-27499, 2009.
55. A. J. Tijsen, Y. M. Pinto, and E. E. Creemers, "Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases," American Journal of Physiology-Heart and Circulatory Physiology, vol. 303, no. 9, pp. H1085-H1095, 2012.
56. Y. Zhang, M. Zhang, M. Zhong, Q. Suo, and K. Lv, "Expression profiles of miRNAs in polarized macrophages," International Journal of Molecular Medicine, vol. 31, no. 4, pp. 797-802, 2013.
57. A. Rudijanto, "The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis," Acta Medica Indonesiana, vol. 39, no. 2, pp. 86-93, 2007.
58. X. Liu, Y. Cheng, J. Yang et al., "Flank sequences of miR-145/143 and their aberrant expression in vascular disease: mechanism and therapeutic application," Journal of the American Heart Association, vol. 2, no. 6, Article ID e000407, 2013.
59. F. Lovren, Y. Pan, A. Quan et al., "MicroRNA-145 targeted therapy reduces atherosclerosis," Circulation, vol. 126, no. 11, supplement 1, pp. S81-S90, 2012.
60. F. Sala, J. F. Aranda, N. Rotllan et al., "MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice," Thrombosis and Haemostasis, vol. 112, no. 4, pp. 796-802, 2014.
61. A. C. Doran, N. Meller, and C. A. McNamara, "Role of smooth muscle cells in the initiation and early progression of atherosclerosis," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 5, pp. 812-819, 2008.
62. E. Ambrosioni, S. Bacchelli, D. Degli Esposti, and C. Borghi, "ACE-inhibitors and experimental atherosclerosis," Clinical and Experimental Hypertension, vol. 15, supplement 1, pp. 157-172, 1993.
63. E. Raitoharju, N. Oksala, and T. Lehtimäki, "MicroRNAs in the atherosclerotic plaque," Clinical Chemistry, vol. 59, no. 12, pp. 1708-1721, 2013.
64. F. Cipollone, L. Felicioni, R. Sarzani et al., "A uniqueMicroRNA signature associated with plaque instability in humans," Stroke, vol. 42, no. 9, pp. 2556-2563, 2011.
65. R. M. K. W. Lee, G. K. Owens, T. Scott-Burden, R. J. Head, M. J. Mulvany, and E. L. Schiffrin, "Pathophysiology of smooth muscle in hypertension," Canadian Journal of Physiology and Pharmacology, vol. 73, no. 5, pp. 574-584, 1995.
66. E. M. Rzucidlo, K. A. Martin, and R. J. Powell, "Regulation of vascular smoothmuscle cell differentiation," Journal of Vascular Surgery, vol. 45, supplement, pp. A25-A32, 2007.
67. G. D. Norata, C. Pinna, F. Zappella et al., "MicroRNA 143-145 deficiency impairs vascular function," International Journal of Immunopathology and Pharmacology, vol. 25, no. 2, pp. 467-474, 2012.
68. B. Hu, J. T. Song, H. Y. Qu et al., "Mechanical stretch suppresses microRNA-145 expression by activating extracellular signalregulated kinase 1/2 and upregulating angiotensin-converting enzyme to alter vascular smooth muscle cell phenotype," PLoS ONE, vol. 9, no. 5, Article ID e96338, 2014.
69. K. M. Turczyńska, M. K. Sadegh, P. Hellstrand, K. Swärd, and S. Albinsson, "MicroRNAs are essential for stretch-induced vascular smooth muscle contractile differentiation via microRNA (miR)-145-dependent expression of L-type calcium channels," The Journal of Biological Chemistry, vol. 287, no. 23, pp. 19199-19206, 2012.
70. S. Moosmang, V. Schulla, A. Welling et al., "Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation," The EMBO Journal, vol. 22, no. 22, pp. 6027-6034, 2003.
71. H. D. Intengan and E. L. Schiffrin, "Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis," Hypertension, vol. 38, no. 3, part 2, pp. 581-587, 2001.
72. J.Meloche, R. Paulin, S. Provencher, and S. Bonnet, "Therapeutic potential of microRNA modulation in pulmonary arterial hypertension," Current Vascular Pharmacology. In press.
73. B. N. Davis-Dusenbery, M. C. Chan, K. E. Reno et al., "Downregulation of Krüppel-like Factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-β and bone morphogenetic protein 4," The Journal of Biological Chemistry, vol. 286, no. 32, pp. 28097-28110, 2011.
74. X. Long and J. M. Miano, "Transforming growth factor-β1 (TGF-β1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells,"The Journal of Biological Chemistry, vol. 286, no. 34, pp. 30119-30129, 2011.
75. S. Yang, H. Cui, N. Xie et al., "MiR-145 regulates myofibroblast differentiation and lung fibrosis," The FASEB Journal, vol. 27, no. 6, pp. 2382-2391, 2013.
76. J. Xu, J. Zhao, G. Evan, C. Xiao, Y. Cheng, and J. Xiao, "Circulating microRNAs: novel biomarkers for cardiovascular diseases," Journal of Molecular Medicine, vol. 90, no. 8, pp. 865-875, 2012.
77. F. Russo, S. Di Bella, V. Bonnici et al., "A knowledge base for the discovery of function, diagnostic potential and drug effects on cellular and extracellular miRNAs," BMC Genomics, vol. 15, supplement 3, p. S4, 2014.
78. E. Bronze-da-Rocha, "MicroRNAs expression profiles in cardiovascular diseases," BioMed Research International, vol. 2014, Article ID 985408, 23 pages, 2014.
79. S. Rawal, P. Manning, and R. Katare, "Cardiovascular microRNAs: As modulators and diagnostic biomarkers of diabetic heart disease," Cardiovascular Diabetology, vol. 13, no. 1, article 44, 2014.
80. S. Dangwal and T. Thum, "MicroRNA therapeutics in cardiovascular disease models," Annual Review of Pharmacology and Toxicology, vol. 54, pp. 185-203, 2014.
81. F. Wahid, A. Shehzad, T. Khan, and Y. Y. Kim, "MicroRNAs: synthesis, mechanism, function, and recent clinical trials," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1803, no. 11, pp. 1231-1243, 2010.
82. M. Ohnaka, A. Marui, K. Yamahara et al., "Effect ofmicroRNA-145 to prevent vein graft disease in rabbits by regulation of smooth muscle cell phenotype," Journal of Thoracic and Cardiovascular Surgery, vol. 148, no. 2, pp. 676.e2-682.e2, 2014.